Relay Therapeutics
RLAY
16.12
+0.21
+1.32%
Relay Therapeutics
US · RLAY
#2273 by market cap
Listed 2020
16.12
+0.21
+1.32%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/5/26
-
Rating change
Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26Market Newswire · 2026/8/10
-
Rating change
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31Market Newswire · 2026/7/22
-
CCORF Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/11/6
-
JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31Market Newswire · 2026/11/7
-
Rating change
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $30Market Newswire · 2026/8/7
-
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $30Market Newswire · 2026/11/5
-
Rating change
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $29Market Newswire · 2026/8/20
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY)TipRanks · 2026/6/18
-
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/11/9
-
Rating change
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31Market Newswire · 2026/8/14
-
Rating change
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $27Market Newswire · 2026/5/21
-
Rating change
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $28Market Newswire · 2026/5/26
-
Rating change
Guggenheim Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $26Market Newswire · 2026/10/28
-
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q3 Revenue $0, Vs. FactSet Est of $1.6MMT Newswires · 2026/11/5
-
Rating change
J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy RatingMarket Newswire · 2026/8/4
-
Rating change
TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy RatingMarket Newswire · 2026/8/7
-
Rating change
JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20Market Newswire · 2026/9/28
-
Rating change
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22Market Newswire · 2026/6/3
-
Rating change
CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29Market Newswire · 2026/7/16
-
Rating change
Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $21Market Newswire · 2026/5/21
-
Rating change
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $20 to $27Market Newswire · 2026/5/20
-
Rating change
Oppenheimer Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18Market Newswire · 2026/5/6
-
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/8/21
-
CCORF Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29Market Newswire · 2026/10/26
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Relay Therapeutics discussion 0 comments